The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Global Therapeutic Vaccines Market Distribution by Type of Vaccine (Antigen vaccine, DNA vaccine and Dendritic vaccine), Method of Vaccine Composition (Autologous vaccine and Allogeneic vaccine), Type of Therapy (Monotherapy and Combination Therapy), Target Disease Indication (Cervical Cancer, Ewing Sarcoma, Glioblastoma, HIV Infection, Ovarian cancer, Prostate Cancer, Tuberculosis, Others), Route of Administration (Intravenous, Intradermal, Subcutaneous, Oral and Others) and Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa and rest of the world): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    May 2022

  • Pages
    365

  • View Count
    1085

Example Insights

Global-Therapeutic-Vaccine-Market-Context-thumb Global-Therapeutic-Vaccine-Market-List-of-Therapeutic-Vaccines-thumb Global-Therapeutic-Vaccine-Market-Distribution-by-Therapeutic-Area-thumb
Global-Therapeutic-Vaccine-Market-Clinical-Research-Landscape-thumb Global-Therapeutic-Vaccine-Market-Grant-Analysis-thumb Global-Therapeutic-Vaccine-Market-Geographical-Activity-thumb
Global-Therapeutic-Vaccine-Market-Start-up-Health-Indexing-thumb Global-Therapeutic-Vaccine-Market-Distribution-by-Disease-Indication-thumb Global-Therapeutic-Vaccine-Market-Distribution-by-Method-of-Composition-thumb

Overview

Unlike the prophylactic vaccines that are designed and administered as a precautionary measure to prevent the occurrence of a disease, researchers have developed therapeutic vaccines intended to alleviate the suffering of patients already infected with the disease. Therapeutic vaccines are not as efficacious as prophylactic vaccines; however, they demonstrate safety, specificity and a long-lasting response across various clinical conditions. These vaccines help the immune system in recognizing a foreign agent and are primarily being developed for viral infections and different types of cancer. Additionally, individuals who are affected with chronic infections but cannot produce enough efficient antibodies can be administered such vaccines. Currently, six therapeutic vaccines are commercially available, including Imlygic®, Provenge® and Tice® which have recently been approved for treatment of melanoma, prostate cancer and bladder cancer, respectively; in addition, over 350 vaccines are under development for various oncological, infectious, hepatological, neurological and autoimmune disorders. 
 
Extensive research is being conducted to improve the overall stability of these therapeutic formulations and a variety of adjuvants (substances with an innate potential to augment an immune response) have been discovered for the development of more versatile vaccine formulations. Further, researchers are also investigating the potential of these vaccines against other chronic disease conditions, including hypertension and autoimmune disorders. Over the last few years, this segment of industry has witnessed substantial partnership activity and investment from various private and public sector investors / investment funds, which have extended financial support to the organizations engaged in R&D. Driven by encouraging clinical trial results, increasing adoption of therapeutic vaccines for treating various clinical conditions and investment in R&D, the therapeutic vaccines market is poised to witness noteworthy growth in the foreseen future.

Scope of the Report

The “Global Therapeutic Vaccines Market, 2022–2035” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution and future opportunities associated with the therapeutic vaccines market. The study underlines an in-depth analysis, highlighting the key drivers and the market trends related to this evolving segment of the pharmaceutical industry. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of therapeutic vaccines, based on several relevant parameters, such as phase of development (clinical and preclinical) of lead candidates, type of vaccine (antigen vaccine, dendritic vaccine, DNA vaccine and peptide vaccine), type of vaccine by method of composition (autologous vaccine and allogeneic vaccine), type of therapy (monotherapy and combination therapy), target disease indication and route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others) and dosing frequency. It also includes a list of players developing therapeutic vaccines along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of key players engaged in the development of therapeutic vaccines, based across North America, Europe and Asia Pacific. Each profile features a brief overview of the company, its financial information (if available), details on its clinical-stage vaccine candidates, recent developments and an informed future outlook.
  • A detailed analysis of completed, ongoing and planned clinical trials of various therapeutic vaccines, based on important parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, target disease indication(s), type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), number of patients enrolled and regional distribution.
  • An in-depth analysis of grants that have been awarded to various research institutes for research related to therapeutic vaccines, during the period, 2016-2022, on the basis of different parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, focus area, study section involved, type of recipient organization and focus area. In addition, it highlights the geographical distribution of recipient organizations, popular NIH departments, prominent program officers, and popular recipient organizations.  
  • An analysis of the partnerships that have been established in this domain since 2016, covering instances of product development and / or commercialization agreements, R&D collaborations, licensing agreements, mergers and acquisitions, clinical trial agreements, and other relevant deals. 
  • An analysis of the various start-ups engaged in the field of therapeutic vaccines, based on relevant parameters, such as number of candidates in discovery, preclinical and clinical phases of development, amount raised in different funding instances and number of partnerships established.
  • A case study on preventive vaccines, along with information on marketed as well as clinical-stage candidates, based on parameters, such as phase of development, route of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others), type of vaccine API (live attenuated vaccine, inactivated vaccine, conjugate vaccine, subunit vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule, and tablet) and target disease indication.
  • A case study on contract manufacturing for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

One of the key objectives of the report was to estimate the existing market size and future growth opportunity associated with therapeutic vaccines market in the mid to long term. Based on parameters, such as adoption rates and expected prices variations for these products, we have developed informed estimates on the likely evolution of the market for the period 2022-2035. 
Our year-wise projections of the current and forecasted opportunity within the therapeutic vaccines market, have further been segmented across different types of vaccines (antigen vaccine, dendritic vaccine, DNA vaccine and peptide vaccine), types of vaccines by method of composition (autologous and allogeneic vaccine), types of therapies (monotherapy and combination), target disease indications, routes of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others) and key geographical regions (North America, Europe and Asia Pacific). 
In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

The opinions and insights presented in the report were influenced by discussions held with senior representatives in the industry. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry players involved in developing therapeutic vaccines?
  • What are the key therapeutic areas for which therapeutic vaccines are being / have been developed?
  • What are the prevalent trends within competitive landscape of therapeutic vaccines?
  • Which geographies are the most active in conducting clinical trials related to therapeutic vaccines?
  • Which are the leading funding organizations providing grants for therapeutic vaccines?
  • What kind of partnership models are commonly adopted by industry and non-industry stakeholders?
  • What are the different initiatives undertaken by start-up players for the development of therapeutic vaccines in the recent past?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of the therapeutic vaccines market and its likely evolution in the mid to long term. 

Chapter 3 provides a general introduction to therapeutic vaccines, including information on their types, characterized by the method of composition and mechanism of action. Additionally, the chapter provides information on the various disease indications for which therapeutic vaccines are being investigated / developed. Further, the chapter features a brief overview of clinical development and approval processes for vaccines and the future perspectives. 

Chapter 4 provides a detailed assessment of the current market landscape of over 300 therapeutic vaccines that are currently being evaluated across different stages of development. It features a comprehensive analysis of the pipeline molecules based on several relevant parameters, such as, phase of development (clinical and preclinical), type of vaccine (antigen vaccine, dendritic vaccine, DNA vaccine, peptide vaccine), type of vaccine by method of composition (autologous vaccine, allogeneic vaccine), type of therapy (monotherapy and combination therapy), dosage (weekly, biweekly, monthly, bimonthly, triweekly), target disease indication, route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others) and dosage frequency.

Chapter 5 includes detailed profiles of key players engaged in the development of therapeutic vaccines, based across North America, Europe and Asia Pacific. Each profile features a brief overview of the company, its financial information (if available), details on its clinical-stage vaccines candidates, recent developments and an informed future outlook.

Chapter 6 provides information on more than 790 completed, ongoing and planned clinical trials of therapeutic vaccines, based on different parameters, such as trial registration year, trial phase, trial recruitment status, study design, trial focus area, target disease indication(s), type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.

Chapter 7 provides an in-depth analysis of more than 500 grants that have been awarded to various research institutes for research related to therapeutic vaccines, during the period, 2016-2022, on the basis of different parameters, such year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, focus area, study section involved, type of recipient organizations and focus area. In addition, it highlights the geographical distribution of recipient organizations, popular NIH departments, prominent program officers, and popular recipient organizations.  

Chapter 8 provides a detailed analysis of the recent collaborations established since 2016. It includes analysis based on relevant parameters, such as year of agreement, type of agreement, therapeutic area, type of partner and regional distribution of partnerships. 

Chapter 9 features an analysis of the various start-ups engaged in development of therapeutic vaccines, based on relevant parameters, such as number of candidates in discovery, preclinical and clinical phases of development, number of partnerships, number of patents, amount raised, number of investors, types of funding and number of deals inked.

Chapter 10 includes an analysis of the big pharma players engaged in the field of therapeutic vaccines, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on parameters, such as number of vaccines under development, type of vaccine, type of vaccine (by method of composition), type of therapy, number of therapeutic areas, number of partnerships, and years of experience.

Chapter 11 presents an insightful market forecast analysis, highlighting the likely growth of the therapeutic vaccines market, till 2035. In order to provide a detailed future outlook, our projections have been segmented across across different types of vaccines (antigen vaccine, dendritic vaccine, DNA vaccine and peptide vaccine), types of vaccines by method of composition (autologous vaccine and allogeneic vaccine), types of therapies (monotherapy and combination), target disease indications, routes of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others) and key geographical regions (North America, Europe and Asia Pacific). 

Chapter 12 features a case study of preventive vaccines, along with information on marketed as well as clinical-stage candidates, based on parameters, such as phase of development, route of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others), type of vaccine API (live attenuated vaccine, inactivated vaccine, conjugate vaccine, subunit vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule, and tablet) and target disease indication.

Chapter 13 presents a case study on contract manufacturing for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

Chapter 14 is a summary of the overall report, which presents insights on the contemporary market trends and the likely evolution of the therapeutics vaccines market.

Chapter 15 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 16 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Therapeutic Vaccines
3.2.1. Classification of Vaccines by Method of Composition
3.2.1.1. Autologous Vaccines
3.2.1.2. Allogeneic Vaccines

3.3. Classification of Vaccines by Mechanism of Action
3.3.1. Antigen Vaccines
3.3.2. Dendritic Vaccines
3.3.3. DNA Vaccines
3.3.4. Peptide Vaccines

3.4 Key Target Indications
3.4.1. Cancer
3.4.2. HIV Infection
3.4.3. HPV Infection
3.4.4. Herpes

3.5. Clinical Development and Approval of Vaccines
3.6. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Therapeutic Vaccines: Pipeline Analysis
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Vaccine
4.2.3. Analysis by Type of Vaccine (by Method of Composition)
4.2.4. Analysis by Type of Therapy
4.2.5. Analysis by Target Disease Indication
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Dosage

4.3. Therapeutic Vaccines: Analysis by Vaccine Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Developers
4.3.5. Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. BioNTech
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Therapeutic Vaccines Portfolio
5.2.4. Recent Developments and Future Outlook

5.3 Brii Biosciences
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Therapeutic Vaccines Portfolio
5.3.4. Recent Developments and Future Outlook

5.4 GlobeImmune
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Therapeutic Vaccines Portfolio
5.4.4. Recent Developments and Future Outlook

5.5 Immatics
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Therapeutic Vaccines Portfolio
5.5.4. Recent Developments and Future Outlook

5.6. Immune Response Biopharma
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Therapeutic Vaccines Portfolio
5.6.4. Recent Developments and Future Outlook

5.7. Immunitor
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Therapeutic Vaccines Portfolio
5.7.4. Recent Developments and Future Outlook

5.8. Inovio Pharmaceuticals
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Therapeutic Vaccines Portfolio
5.8.4. Recent Developments and Future Outlook

5.9. Moderna
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Therapeutic Vaccines Portfolio
5.9.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Therapeutic Vaccines: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.3. Analysis by Trial Phase
6.3.4. Analysis by Trial Recruitment Status
6.3.5. Analysis by Study Design
6.3.6. Analysis by Trial Focus Area
6.3.7. Analysis by Target Disease Indication
6.3.8. Analysis by Type of Sponsor / Collaborator
6.3.9. Most Active Players: Analysis by Number of Registered Trials
6.3.10. Geographical Analysis by Number of Registered Trials
6.3.11. Geographical Analysis by Enrolled Patient Population

7. ACADEMIC GRANT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Therapeutic Vaccines: Academic Grant Analysis
7.3.1. Analysis by Year of Grant Award
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Administering Institute Center
7.3.4. Analysis by Support Period
7.3.5. Analysis by Administering Institute Center and Support Period
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Purpose of Grant Award
7.3.8. Analysis by Activity Code
7.3.9. Analysis by Study Section Involved
7.3.10. Analysis by Type of Recipient Organization
7.3.11. Word Cloud Analysis: Emerging Focus Areas
7.3.12. Geographical Distribution of Recipient Organizations
7.3.13. Popular NIH Departments: Analysis by Number of Grants
7.3.14. Prominent Program Officers: Analysis by Number of Grants
7.3.15. Popular Recipient Organizations: Analysis by Number of Grants

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Therapeutic Vaccines: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partner
8.3.4. Analysis by Type of Partnership and Type of Partner
8.3.5. Analysis by Focus Area
8.3.6. Analysis by Therapeutic Area
8.3.7. Most Active Players: Analysis by Number of Partnerships

8.3.8. Regional Analysis
8.3.8.1. Intercontinental and Intracontinental Agreements

9. START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Start-ups in Therapeutic Vaccines Market
9.2.1. Analysis by Location of Headquarters
9.3. Benchmarking of Start-ups
9.3.1. Analysis by Supplier Strength
9.3.2. Analysis by Pipeline Strength
9.3.3. Analysis by Pipeline Maturity
9.3.4. Analysis by Financial Investment
9.3.5. Analysis by Partnership Activity
9.3.6. Start-ups Health Indexing: Roots Analysis Perspective

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Therapeutic Vaccines Market, 2022-2035
10.4. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Type of Vaccine
10.5. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Method of Vaccine Composition
10.6. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Type of Therapy
10.7. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Target Disease Indication
10.8. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Route of Administration

10.9. Global Therapeutic Vaccines Market, 2022-2035: Geographical Distribution
10.9.1. Therapeutic Vaccines Market in US, 2022-2035
10.9.2. Therapeutic Vaccines Market in Canada, 2022-2035
10.9.3. Therapeutic Vaccines Market in UK, 2022-2035
10.9.4. Therapeutic Vaccines Market in Germany, 2022-2035
10.9.5. Therapeutic Vaccines Market in France, 2022-2035
10.9.6. Therapeutic Vaccines Market in Italy, 2022-2035
10.9.7. Therapeutic Vaccines Market in Spain, 2022-2035
10.9.8. Therapeutic Vaccines Market in Australia, 2022-2035
10.9.9. Therapeutic Vaccines Market in Japan, 2022-2035
10.9.10. Therapeutic Vaccines Market in Korea, 2022-2035
10.9.11. Therapeutic Vaccines Market in Brazil, 2022-2035
10.9.12. Therapeutic Vaccines Market in Israel, 2022-2035

10.10. Global Therapeutic Vaccines Market, 2022-2035: Individual Product Sales Forecast
10.10.1. ASP0113
10.10.1.1. Target Patient Population
10.10.1.2. Sales Forecast

10.10.2. Copaxone
10.10.2.1. Target Patient Population
10.10.2.2. Sales Forecast

10.10.3. Galinpepimut-S
10.10.3.1. Target Patient Population
10.10.3.2. Sales Forecast

10.10.4. Hepcortespenlisimut-L
10.10.4.1. Target Patient Population
10.10.4.2. Sales Forecast

10.10.5. ICT-107
10.10.5.1. Target Patient Population
10.10.5.2. Sales Forecast

10.10.6. IR103
10.10.6.1. Target Patient Population
10.10.6.2. Sales Forecast

10.10.7. MGN1703
10.10.7.1. Target Patient Population
10.10.7.2. Sales Forecast

10.10.8. Neuronata-R
10.10.8.1. Target Patient Population
10.10.8.2. Sales Forecast

10.10.9. OncoVax
10.10.9.1. Target Patient Population
10.10.9.2. Sales Forecast

10.10.10. OSE2101
10.10.10.1. Target Patient Population
10.10.10.2. Sales Forecast

10.10.11. Provenge
10.10.11.1. Target Patient Population
10.10.11.2. Sales Forecast

10.10.12. REMUNE
10.10.12.1. Target Patient Population
10.10.12.2. Sales Forecast

10.10.13. RIAVAX
10.10.13.1. Target Patient Population
10.10.13.2. Sales Forecast

10.10.14. V503
10.10.14.1. Target Patient Population
10.10.14.2. Sales Forecast

10.10.15. V7
10.10.15.1. Target Patient Population
10.10.15.2. Sales Forecast

10.10.16. VGX-3100
10.10.16.1. Target Patient Population
10.10.16.2. Sales Forecast

10.10.17. Vigil
10.10.17.1. Target Patient Population
10.10.17.2. Sales Forecast

11. CASE STUDY: GLOBAL PREVENTIVE VACCINES
11.1. Chapter Overview
11.2. Preventive Vaccines: Overall Market Landscape
11.2.1. Marketed Vaccines Landscape
11.2.2. Clinical-Stage Vaccines Landscape
11.2.3. Analysis by Phase of Development
11.2.4. Analysis by Route of Administration
11.2.5. Analysis by Type of Vaccine API
11.2.6. Analysis by Dosage Form
11.2.7. Analysis by Target Disease Indication
11.2.8. Key Industry Players: Analysis by Number of Vaccines in Clinical Development
11.2.9. Key Non-Industry Players: Analysis by Number of Vaccines in Clinical Development

12. CASE STUDY: VACCINE CONTRACT MANUFACTURING MARKET
12.1 Chapter Overview
12.2. Vaccine Contract Manufacturers: Overall Market Landscape
12.2.1 Analysis by Year of Establishment
12.2.2. Analysis by Company Size and Geographical Location
12.2.3. Analysis by Geography
12.2.4. Analysis by Type of Service(s) Offered
12.2.5. Analysis by Scale of Operation
12.2.6. Analysis by Type of Expression System(s) Used
12.2.7. Analysis by Type of Vaccines Manufactured

13. CONCLUDING REMARKS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Difference between Preventive Vaccines and Therapeutic Vaccines
Figure 3.2 Different Routes of Vaccine Administration
Figure 4.1 Therapeutic Vaccines: Distribution by Phase of Development
Figure 4.2 Therapeutic Vaccines: Distribution by Type of Vaccine
Figure 4.3 Therapeutic Vaccines: Distribution by Type of Vaccine (by Method of Composition)
Figure 4.4 Therapeutic Vaccines: Distribution by Type of Therapy
Figure 4.5 Therapeutic Vaccines: Distribution by Target Disease Indication
Figure 4.6 Therapeutic Vaccines: Distribution by Route of Administration
Figure 4.7 Therapeutic Vaccines: Distribution by Dosage
Figure 4.8 Therapeutic Vaccines Developers: Distribution by Type of Developers
Figure 4.9 Therapeutic Vaccines Developers: Distribution by Year of Establishment
Figure 4.10 Therapeutic Vaccines Developers: Distribution by Company Size
Figure 4.11 Therapeutic Vaccines Developers: Distribution by Location of Headquarters
Figure 4.12 Leading Developers
Figure 4.13 Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
Figure 5.1 BioNTech: Annual Revenues, 2016-2021 (USD Million)
Figure 5.2 Brii Biosciences: Annual Revenues, 2016-2021 (USD Million)
Figure 5.3 GlobeImmune: Annual Revenues, 2016-2021 (USD Million)
Figure 5.4 Immatics: Annual Revenues, 2016-2021 (USD Million)
Figure 5.5 Immune Response Biopharma: Annual Revenues, 2016-2021 (USD Million)
Figure 5.6 Inovio Pharmaceuticals: Annual Revenues, 2016-2021 (USD Million)
Figure 5.7 Moderna: Annual Revenues, 2016-2021 (USD Million)
Figure 6.1 Clinical Trial Analysis: Scope and Methodology
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2010-2022
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.6 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 6.7 Clinical Trial Analysis: Distribution by Study Design
Figure 6.8 Clinical Trial Analysis: Distribution by Trial Focus Area
Figure 6.9 Clinical Trial Analysis: Distribution by Target Disease Indication
Figure 6.10 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.11 Most Active Players: Distribution by Number of Registered Trials
Figure 6.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 6.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.1 Grant Analysis: Cumulative Year-wise Trend, 2016-2022
Figure 7.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million) 2016-2022
Figure 7.3 Grant Analysis: Distribution by Administering Institute Center
Figure 7.4 Grant Analysis: Distribution by Support Period
Figure 7.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 7.6 Grant Analysis: Distribution by Type of Grant Application
Figure 7.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 7.8 Grant Analysis: Distribution by Activity Code
Figure 7.9 Grant Analysis: Distribution by Study Section Involved
Figure 7.10 Grant Analysis: Distribution by Type of Recipient Organization
Figure 7.11 Word Cloud Analysis: Emerging Focus Areas
Figure 7.12 Grant Analysis: Geographical Distribution of Recipient Organizations
Figure 7.13 Popular NIH Departments: Distribution by Number of Grants
Figure 7.14 Prominent Program Officers: Distribution by Number of Grants
Figure 7.15 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Figure 8.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.6 Partnerships and Collaborations: Distribution by Focus Areas
Figure 8.7 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.8 Most Active Players: Distribution by Number of Partnerships
Figure 8.9 Partnerships and Collaborations: Regional Distribution
Figure 8.9.1 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Startup-Health Indexing: Distribution by Location of Headquarters
Figure 9.2 Startup-Health Indexing: Distribution by Supplier Strength
Figure 9.3 Startup-Health Indexing: Distribution by Pipeline Strength
Figure 9.4 Startup-Health Indexing: Distribution by Pipeline Maturity
Figure 9.5 Startup-Health Indexing: Distribution by Financial Investment
Figure 9.6 Startup-Health Indexing: Distribution by Partnership Activity
Figure 9.7 Startup-Health Indexing: Roots Analysis Perspective
Figure 9.8 Spider Web Analysis: Leading Companies
Figure 10.1 Global Therapeutic Vaccines Market, 2022-2035 (USD Million)
Figure 10.2 Global Therapeutic Vaccines Market: Distribution by Type of Vaccine, 2022-2035
Figure 10.3 Global Therapeutic Vaccines Market: Distribution by Method of Vaccine Composition, 2022-2035
Figure 10.4 Global Therapeutic Vaccines Market: Distribution by Type of Therapy, 2022-2035
Figure 10.5 Global Therapeutic Vaccines Market: Distribution by Target Disease Indication, 2022-2035
Figure 10.6 Global Therapeutic Vaccines Market: Distribution by Route of Administration, 2022-2035
Figure 10.7 Therapeutic Vaccines Market in US, 2022-2035
Figure 10.8 Therapeutic Vaccines Market in Canada, 2022-2035
Figure 10.9 Therapeutic Vaccines Market in UK, 2022-2035
Figure 10.10 Therapeutic Vaccines Market in Germany, 2022-2035
Figure 10.11 Therapeutic Vaccines Market in France, 2022-2035
Figure 10.12 Therapeutic Vaccines Market in Italy, 2022-2035
Figure 10.13 Therapeutic Vaccines Market in Spain, 2022-2035
Figure 10.14 Therapeutic Vaccines Market in Australia, 2022-2035
Figure 10.15 Therapeutic Vaccines Market in Japan, 2022-2035
Figure 10.16 Therapeutic Vaccines Market in Korea, 2022-2035
Figure 10.17 Therapeutic Vaccines Market in Brazil, 2022-2035
Figure 10.18 Therapeutic Vaccines Market in Israel, 2022-2035
Figure 10.19 ASP0113 (Astellas Pharma): Estimated Sales, 2022-2035 (USD Million)
Figure 10.20 Copaxone (Teva Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Figure 10.21 Galinpeptimut-S (Sellas Life Sciences): Estimated Sales, 2024-2035 (USD Million)
Figure 10.22 Hepcortespenlisimut-L (Immunitor): Estimated Sales, 2022-2035 (USD Million)
Figure 10.23 ICT-107 (Precision Life Sciences): Estimated Sales, 2022-2035 (USD Million)
Figure 10.24 IR103 (Immune Response Biopharma): Estimated Sales, 2022-2035 (USD Million)
Figure 10.25 MGN1703 (Mologen): Estimated Sales, 2022-2035 (USD Million)
Figure 10.26 Neuronata-R (OptiNose): Estimated Sales, 2027-2035 (USD Million)
Figure 10.27 OncoVax (Corestem): Estimated Sales, 2023-2035 (USD Million)
Figure 10.28 OSE2101 (OSE Immunotherapeutics): Estimated Sales, 2022-2035 (USD Million)
Figure 10.29 Provenge (Dendreon Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Figure 10.30 REMUNE (Immune Response Biopharma): Estimated Sales, 2022-2035 (USD Million)
Figure 10.31 RIAVAX (Kael-GemVax): Estimated Sales, 2024-2035 (USD Million)
Figure 10.32 V503 (Merck): Estimated Sales, 2027-2035 (USD Million)
Figure 10.33 V7 (Immunitor): Estimated Sales, 2022-2035 (USD Million)
Figure 10.34 VGX-3100 (Inovio Pharmaceuticals): Estimated Sales, 2023-2035 (USD Million)
Figure 10.35 Vigil (Gradalis): Estimated Sales, 2025-2035 (USD Million)
Figure 11.1 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
Figure 11.2 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
Figure 11.3 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
Figure 11.4 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
Figure 11.5 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
Figure 11.6 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
Figure 11.7 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
Figure 11.8 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
Figure 12.1 Vaccine CMOs: Distribution by Year of Establishment
Figure 12.2 Vaccine CMOs: Distribution by Company Size and Geographical Location
Figure 12.3 World Map Representation: Distribution by Geography
Figure 12.4 Vaccine CMOs: Distribution by Types of Service(s) Offered
Figure 12.5 Vaccine CMOs: Distribution by Additional Services Offered and Location of Headquarters
Figure 12.6 Vaccine CMOs: Distribution by Scale of Operation
Figure 12.7 Vaccine CMOs: Distribution by Type of Expression System(s) Used
Figure 12.8 Vaccine CMOs: Distribution by Type of Vaccine Manufactured
Figure 13.1 Concluding Remarks: Overall Market Landscape
Figure 13.2 Concluding Remarks: Clinical Trial Analysis
Figure 13.3 Concluding Remarks: Academic Grant Analysis
Figure 13.4 Concluding Remarks: Partnerships and Collaborations
Figure 13.5 Concluding Remarks: Start-up Health Indexing
Figure 13.6 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Vaccines for Cancer Treatment
Table 3.2 Vaccines for HIV Treatment
Table 3.3 Vaccines for HPV Treatment
Table 3.4 Vaccines for Herpes Treatment
Table 4.1 List of Therapeutic Vaccines
Table 5.1 Global Therapeutic Vaccines: List of Companies Profiled
Table 5.2 BioNTech: Company Snapshot
Table 5.3 Vaccine Profile: BNT-111
Table 5.4 Vaccine Profile: BNT-112
Table 5.5 Vaccine Profile: BNT-113
Table 5.6 Vaccine Profile: BNT-115
Table 5.7 Vaccine Profile: BNT-116
Table 5.8 Vaccine Profile: BNT-122
Table 5.9 Vaccine Profile: W_pro1
Table 5.10 Vaccine Profile: HPV Vaccine
Table 5.11 Vaccine Profile: IVAC MUTANOME
Table 5.12 Vaccine Profile: RBL001/RBL002
Table 5.13 Vaccine Profile: NEO-PV-01
Table 5.14 BioNTech: Recent Developments and Future Outlook
Table 5.15 Brii Biosciences: Company Snapshot
Table 5.16 Vaccine Profile: Bri-179
Table 5.17 Vaccine Profile: Bri-835
Table 5.18 Vaccine Profile: Bri-778
Table 5.19 Vaccine Profile: Bri-732
Table 5.20 Vaccine Profile: Bri-296
Table 5.21 Brii Biosciences: Recent Developments and Future Outlook
Table 5.22 GlobeImmune: Company Snapshot
Table 5.23 Vaccine Profile: GI-6301
Table 5.24 Vaccine Profile: GI-6207
Table 5.25 Vaccine Profile: GI-4000
Table 5.26 Vaccine Profile: GS-4774
Table 5.27 Vaccine Profile: GI-5005
Table 5.28 GlobeImmune: Recent Developments and Future Outlook
Table 5.29 Immatics: Company Snapshot
Table 5.30 Vaccine Profile: APVAC
Table 5.31 Vaccine Profile: IMA901
Table 5.32 Vaccine Profile: IMA910
Table 5.33 Vaccine Profile: IMA950
Table 5.34 Vaccine Profile: IMA970A
Table 5.35 Immatics: Recent Developments and Future Outlook
Table 5.36 Immune Response Biopharma: Company Snapshot
Table 5.37 Vaccine Profile: IR103
Table 5.38 Vaccine Profile: REMUNE
Table 5.39 Vaccine Profile: NeuroVax
Table 5.40 Vaccine Profile: RAVAX
Table 5.41 Vaccine Profile: Zorcell
Table 5.42 Immune Response Biopharma: Recent Developments and Future Outlook
Table 5.43 Immunitor: Company Snapshot
Table 5.44 Vaccine Profile: Atherosclerosis Vaccine
Table 5.45 Vaccine Profile: V3-MOMMO
Table 5.46 Vaccine Profile: Hepcortespenlisimut-L
Table 5.47 Vaccine Profile: V-Boost
Table 5.48 Vaccine Profile: V3-OVA
Table 5.49 Vaccine Profile: V3-Myoma
Table 5.50 Vaccine Profile: V3-Cervix
Table 5.51 Vaccine Profile: V7
Table 5.52 Vaccine Profile: V3-X
Table 5.53 Vaccine Profile: V3-P
Table 5.54 Vaccine Profile: V-Endo
Table 5.55 Vaccine Profile: V8
Table 5.56 Vaccine Profile: V-SARS
Table 5.57 Immunitor: Recent Developments and Future Outlook
Table 5.58 Innovio Pharmaceuticals: Company Snapshot
Table 5.59 Vaccine Profile: VGX-3100
Table 5.60 Vaccine Profile: INO-3107
Table 5.61 Vaccine Profile: INO-5401
Table 5.62 Vaccine Profile: INO-5151
Table 5.63 Vaccine Profile: INO-3112
Table 5.64 Vaccine Profile: INO-5150
Table 5.65 Vaccine Profile: INO-3106
Table 5.66 Vaccine Profile: INO-1800
Table 5.67 Innovio Pharmaceuticals: Recent Developments and Future Outlook
Table 5.68 Moderna: Company Snapshot
Table 5.69 Vaccine Profile: mRNA-4157
Table 5.70 Vaccine Profile: mRNA-3927
Table 5.71 Vaccine Profile: mRNA-3705
Table 5.72 Vaccine Profile: mRNA-3745
Table 5.73 Vaccine Profile: mRNA-5671
Table 5.74 Vaccine Profile: mRNA-2752
Table 5.75 Moderna: Recent Developments and Future Outlook
Table 8.1 Global Therapeutic Vaccines: List of Partnerships and Collaborations, 2016-2022
Table 9.1 Therapeutic Vaccines Start-ups: Distribution by Location of Headquarters
Table 10.1 Global Therapeutic Vaccines: Summary of the Competitive Insights
Table 11.1 List of Marketed Preventive Vaccines
Table 11.2 List of Clinical-Stage Preventive Vaccines
Table 12.1 Vaccine Contract Manufacturers: List of Service Providers
Table 12.2 Vaccine CMOs: Information on Type of Service(s) Offered
Table 12.3 Vaccine CMOs: Information on Scale of Operation
Table 12.4 Vaccine CMOs: Information on Type of Expression System(s) Used
Table 12.5 Vaccine CMOs: Information on Type of Vaccines Manufactured
Table 14.1 Therapeutic Vaccines: Distribution by Phase of Development
Table 14.2 Therapeutic Vaccines: Distribution by Type of Vaccine
Table 14.3 Therapeutic Vaccines: Distribution by Type of Vaccine (by Method of Composition)
Table 14.4 Therapeutic Vaccines: Distribution by Type of Therapy
Table 14.5 Therapeutic Vaccines: Distribution by Target Disease Indication
Table 14.6 Therapeutic Vaccines: Distribution by Route of Administration
Table 14.7 Therapeutic Vaccines: Distribution by Dosage
Table 14.8 Therapeutic Vaccines Developers: Distribution by Type of Developers
Table 14.9 Therapeutic Vaccines Developers: Distribution by Year of Establishment
Table 14.10 Therapeutic Vaccines Developers: Distribution by Company Size
Table 14.11 Therapeutic Vaccines Developers: Distribution by Location of Headquarters
Table 14.12 Leading Developers
Table 14.13 Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
Table 14.14 BioNTech: Annual Revenues, 2016-2021 (USD Million)
Table 14.15 Brii Biosciences: Annual Revenues, 2016-2021 (USD Million)
Table 14.16 GlobeImmune: Annual Revenues, 2016-2021 (USD Million)
Table 14.17 Immatics: Annual Revenues, 2016-2021 (USD Million)
Table 14.18 Immune Response Biopharma: Annual Revenues, 2016-2021 (USD Million)
Table 14.19 Inovio Pharmaceuticals: Annual Revenues, 2016-2021 (USD Million)
Table 14.20 Moderna: Annual Revenues, 2016-2021 (USD Million)
Table 14.21 Clinical Trial Analysis: Scope and Methodology
Table 14.22 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
Table 14.23 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2010-2022
Table 14.24 Clinical Trial Analysis: Distribution by Trial Phase
Table 14.25 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 14.26 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 14.27 Clinical Trial Analysis: Distribution by Study Design
Table 14.28 Clinical Trial Analysis: Distribution by Trial Focus Area
Table 14.29 Clinical Trial Analysis: Distribution by Target Disease Indication
Table 14.30 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 14.31 Most Active Players: Distribution by Number of Registered Trials
Table 14.32 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 14.33 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 14.34 Grant Analysis: Cumulative Year-wise Trend, 2016-2022
Table 14.35 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million) 2016-2022
Table 14.36 Grant Analysis: Distribution by Administering Institute Center
Table 14.37 Grant Analysis: Distribution by Support Period
Table 14.38 Grant Analysis: Distribution by Administering Institute Center and Support Period
Table 14.39 Grant Analysis: Distribution by Type of Grant Application
Table 14.40 Grant Analysis: Distribution by Purpose of Grant Award
Table 14.41 Grant Analysis: Distribution by Activity Code
Table 14.42 Grant Analysis: Distribution by Study Section Involved
Table 14.43 Grant Analysis: Distribution by Type of Recipient Organization
Table 14.44 Grant Analysis: Geographical Distribution of Recipient Organizations
Table 14.45 Popular NIH Departments: Distribution by Number of Grants
Table 14.46 Prominent Program Officers: Distribution by Number of Grants
Table 14.47 Popular Recipient Organizations: Distribution by Number of Grants
Table 14.48 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2022
Table 14.49 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.50 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Table 14.51 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 14.52 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.53 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 14.54 Most Active Players: Distribution by Number of Partnerships
Table 14.55 Partnerships and Collaborations: Regional Distribution
Table 14.56 Startup-Health Indexing: Distribution by Location of Headquarters
Table 14.57 Startup-Health Indexing: Distribution by Supplier Strength
Table 14.58 Startup-Health Indexing: Distribution by Pipeline Strength
Table 14.59 Startup-Health Indexing: Distribution by Pipeline Maturity
Table 14.60 Startup-Health Indexing: Distribution by Financial Investment
Table 14.61 Startup-Health Indexing: Distribution by Partnership Activity
Table 14.62 Startup-Health Indexing: Roots Analysis Perspective
Table 14.63 Global Therapeutic Vaccines Market, 2022-2035 (USD Million)
Table 14.64 Global Therapeutic Vaccines Market: Distribution by Type of Vaccine, 2022-2035
Table 14.65 Global Therapeutic Vaccines Market: Distribution by Method of Vaccine Composition, 2022-2035
Table 14.66 Global Therapeutic Vaccines Market: Distribution by Type of Therapy, 2022-2035
Table 14.67 Global Therapeutic Vaccines Market: Distribution by Target Disease Indication, 2022-2035
Table 14.68 Global Therapeutic Vaccines Market: Distribution by Route of Administration, 2022-2035
Table 14.69 Therapeutic Vaccines Market in US, 2022-2035
Table 14.70 Therapeutic Vaccines Market in Canada, 2022-2035
Table 14.71 Therapeutic Vaccines Market in UK, 2022-2035
Table 14.72 Therapeutic Vaccines Market in Germany, 2022-2035
Table 14.73 Therapeutic Vaccines Market in France, 2022-2035
Table 14.74 Therapeutic Vaccines Market in Italy, 2022-2035
Table 14.75 Therapeutic Vaccines Market in Spain, 2022-2035
Table 14.76 Therapeutic Vaccines Market in Australia, 2022-2035
Table 14.77 Therapeutic Vaccines Market in Japan, 2022-2035
Table 14.78 Therapeutic Vaccines Market in Korea, 2022-2035
Table 14.79 Therapeutic Vaccines Market in Brazil, 2022-2035
Table 14.80 Therapeutic Vaccines Market in Israel, 2022-2035
Table 14.81 ASP0113 (Astellas Pharma): Estimated Sales, 2022-2035 (USD Million)
Table 14.82 Copaxone (Teva Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Table 14.83 Galinpeptimut-S (Sellas Life Sciences): Estimated Sales, 2024-2035 (USD Million)
Table 14.84 Hepcortespenlisimut-L (Immunitor): Estimated Sales, 2022-2035 (USD Million)
Table 14.85 ICT-107 (Precision Life Sciences): Estimated Sales, 2022-2035 (USD Million)
Table 14.86 IR103 (Immune Response Biopharma): Estimated Sales, 2022-2035 (USD Million)
Table 14.87 MGN1703 (Mologen): Estimated Sales, 2022-2035 (USD Million)
Table 14.88 Neuronata-R (OptiNose): Estimated Sales, 2027-2035 (USD Million)
Table 14.89 OncoVax (Corestem): Estimated Sales, 2023-2035 (USD Million)
Table 14.90 OSE2101 (OSE Immunotherapeutics): Estimated Sales, 2022-2035 (USD Million)
Table 14.91 Provenge (Dendreon Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Table 14.92 REMUNE (Immune Response Biopharma): Estimated Sales, 2022-2035 (USD Million)
Table 14.93 RIAVAX (Kael-GemVax): Estimated Sales, 2024-2035 (USD Million)
Table 14.94 V503 (Merck): Estimated Sales, 2027-2035 (USD Million)
Table 14.95 V7 (Immunitor): Estimated Sales, 2022-2035 (USD Million)
Table 14.96 VGX-3100 (Inovio Pharmaceuticals): Estimated Sales, 2023-2035 (USD Million)
Table 14.97 Vigil (Gradalis): Estimated Sales, 2025-2035 (USD Million)
Table 14.98 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
Table 14.99 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
Table 14.100 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
Table 14.101 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
Table 14.102 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
Table 14.103 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
Table 14.104 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
Table 14.105 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
Table 14.106 Vaccine CMOs: Distribution by Year of Establishment
Table 14.107 Vaccine CMOs: Distribution by Company Size and Geographical Location
Table 14.108 Vaccine CMOs: Distribution by Types of Service(s) Offered
Table 14.109 Vaccine CMOs: Distribution by Additional Services Offered and Location of Headquarters
Table 14.110 Vaccine CMOs: Distribution by Scale of Operation
Table 14.111 Vaccine CMOs: Distribution by Type of Expression System(s) Used
Table 14.112 Vaccine CMOs: Distribution by Type of Vaccine Manufactured

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 3D Medicines
  2. Abivax
  3. AC Immune
  4. Adaptive Biotechnologies
  5. Aduro Biotech
  6. Advaxis
  7. AFFiRiS 
  8. Altimmune
  9. ApolloBio
  10. Arbutus Biopharma
  11. Archivel Farma 
  12. Argos Therapeutics
  13. Astellas Pharma
  14. Aston Sci.
  15. AstraZeneca
  16. AVAX Technologies
  17. Axon Neuroscience
  18. Bavarian Nordic
  19. Beijing Genomics Institute
  20. Bellicum Pharmaceuticals
  21. Bionor Immuno
  22. BioNTech
  23. Biosantech
  24. Brii Biosciences
  25. Bristol Myers Squibb
  26. Cancer Insight
  27. Cancer Vaccines
  28. Chinook Therapeutics 
  29. Chongqing Jiachen Biotechnology
  30. Corestem
  31. CuraVac
  32. Cure&Sure Biotech
  33. CureVac
  34. CYTLIMIC 
  35. Dana-Farber Cancer Institute
  36. DCPrime
  37. Dendreon Pharmaceuticals
  38. Dynavax Technologies
  39. EMD Serono
  40. Enterome
  41. Epimmune
  42. eTheRNA immunotherapies
  43. European Oncology Clinical Trial Group
  44. European Network of Gynaecological Oncological Trial Groups (ENGOT) 
  45. FIT Biotech
  46. Frame Therapeutics
  47. Frontier Biotechnologies 
  48. Galena Biopharma
  49. GeneCure Biotechnologies
  50. Genentech
  51. Geneos Therapeutics
  52. Genexine
  53. Genocea Biosciences
  54. Genticel
  55. Gilead Sciences
  56. GlaxoSmithKline
  57. GlobeImmune
  58. Gradalis
  59. Gritstone bio
  60. Hangzhou Neoantigen Therapeutics
  61. Helocyte
  62. Ichor Medical Systems
  63. Immatics Biotechnologies
  64. Immune Design
  65. Immune Response BioPharma
  66. Immunicum
  67. Immunitor
  68. ImmunityBio
  69. ImmunoCellular Therapeutics
  70. Immunomic Therapeutics
  71. Immunor
  72. ImmunoVaccine Technologies
  73. Immunovative Therapies
  74. ImmusanT
  75. Immutep
  76. Incyte
  77. InnaVirVax
  78. Inovio Pharmaceuticals
  79. Invectys
  80. iOncologi
  81. ISA Pharmaceuticals
  82. Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson)
  83. Janssen Vaccines & Prevention (a subsidiary of Johnson & Johnson)
  84. GemVax & KAEL
  85. Kun Tuo
  86. Laboratorios Silanes
  87. LG Life Sciences
  88. Eli Lilly 
  89. MabVax Therapeutics
  90. Madison Vaccines
  91. Marker Therapeutics
  92. Medigene
  93. MedImmune
  94. Memorial Sloan Kettering Cancer Center
  95. Merck
  96. Ministry of Health and Family Welfare (MoHFW)
  97. Moderna
  98. MOLOGEN
  99. Morphogenesis
  100. Mymetics 
  101. NantBioScience (a subsidiary of NantWorks)
  102. National Heart, Lung, and Blood Institute (NHLBI)
  103. NEC OncoImmunity
  104. Nektar Therapeutics
  105. NewLink Genetics
  106. Nobelpharma
  107. Nordic Society of Gynaecological Oncology (NSGO)
  108. Nouscom
  109. Novartis Pharmaceuticals
  110. NovaRx 
  111. NuGenerex Immuno-Oncology
  112. Nykode Therapeutics
  113. OncBioMune Pharmaceuticals
  114. OncoPep
  115. OncoTherapy Science
  116. Origimm Biotechnology (acquired by Sanofi)
  117. OSE Immunotherapeutics
  118. Oxford Vacmedix
  119. PapiVax Biotech
  120. Parker Institute for Cancer Immunotherapy
  121. PCI Biotech 
  122. PDC*line Pharma
  123. Peptinov
  124. Pfizer
  125. Precision BioSciences 
  126. Precision Life Sciences
  127. Profectus BioSciences
  128. QIAGEN
  129. Quantoom Biosciences
  130. Regeneron Pharmaceuticals
  131. ReiThera
  132. Replicate Bioscience
  133. RhoVac
  134. Rigontec (acquired by Merck)
  135. ROVI Pharmaceuticals
  136. Sanofi 
  137. SciVac Therapeutics 
  138. Selecta Biosciences
  139. SELLAS Life Sciences
  140. Shenzhen BioScien Pharmaceuticals 
  141. Stemirna Therapeutics
  142. Stemline Therapeutics
  143. Teva Pharmaceuticals
  144. Themis Medicare
  145. Thyas
  146. Translate Bio (acquired by Sanofi)
  147. UConn Health
  148. Ultimovacs
  149. University of Oxford 
  150. University of Pennsylvania
  151. Vaccinogen
  152. Vaccitech
  153. VaxEquity
  154. VAXIMM
  155. Vaxine
  156. VAXON Biotech
  157. VBI Vaccines
  158. Vertex
  159. Vical
  160. ViciniVax
  161. Wistar Institute
  162. XEME Biopharma

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com